Shares of Becton Dickinson (BDX) tumbled 5.45% in pre-market trading on Thursday after the medical device maker reported mixed second-quarter results and lowered its full-year profit forecast due to the potential impact of tariffs.

For the fiscal second quarter ended March 31, Becton Dickinson reported adjusted earnings of $3.35 per share, beating analyst estimates of $3.28. However, quarterly revenue of $5.27 billion fell short of Wall Street's expectations of $5.35 billion, despite growing 4.5% year-over-year. The company's Medical segment saw strong 12.7% growth, but this was offset by weakness in other areas, particularly the Life Sciences segment which was impacted by global research funding cuts.

The main driver of the stock decline appears to be Becton Dickinson's reduced profit outlook for fiscal year 2025. The company now expects full-year adjusted earnings per share of $14.06 to $14.34, down from its previous guidance of $14.30 to $14.60. This reduction is primarily due to an estimated $0.25 per share impact from recently announced tariffs. While Becton Dickinson raised the lower end of its revenue forecast to $21.8 billion from $21.7 billion, maintaining the upper end at $21.9 billion, investors seem focused on the profit warning. Management noted there is still "a high degree of uncertainty on the future of the tariff environment," though the company has taken steps to mitigate near-term tariff risks.